Does Rallies show 13F holders for PHIO?

Yes. Rallies tracks hedge fund and 13F ownership data for PHIO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PHIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PHIO. It does not provide personalized investment advice.

PHIO (Phio Pharmaceuticals Corp. Common Stock) Stock Analysis - Hedge Fund Holdings

Phio Pharmaceuticals Corp. Common Stock (PHIO) is a publicly traded Healthcare sector company. As of May 21, 2026, PHIO trades at $1.06 with a market cap of $12.55M and a P/E ratio of -0.74. PHIO moved +0.00% today. Year to date, PHIO is -7.69%; over the trailing twelve months it is -40.98%. Its 52-week range spans $0.81 to $9.79. Analyst consensus is buy with an average price target of $14.00. Rallies surfaces PHIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PHIO stock?

Hedge funds tracked by Rallies that own PHIO include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Phio Pharmaceuticals Corp. Common Stock.

PHIO Key Metrics

Key financial metrics for PHIO
Metric	Value
Price	$1.06
Market Cap	$12.55M
P/E Ratio	-0.74
EPS	$-1.45
Dividend Yield	0.00%
52-Week High	$9.79
52-Week Low	$0.81
Volume	21
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-8.70M
Gross Margin	0.00%

Top Hedge Funds Holding PHIO

Citadel Advisors holds 44.53K shares of PHIO, changed +105.27% as of Dec 31, 2024.

Latest PHIO News

Phio to Host May 19 Fireside Chat as PH-762 Delivers 65% Response Rate — May 12, 2026
Phio Secures U.S. cGMP Manufacturing for PH-762 After 65% Response in Phase 1b — Mar 30, 2026
Phio to Present Phase 1b PH-762 Data with 65% cSCC Response and 85% Highest-Dose Response — Mar 23, 2026
Phio Pharmaceuticals Completes PH-762 Phase 1b Trial, Raises $23.7 M — Mar 5, 2026
Phio Names New CFO, SVP Regulatory to Drive PH-762 Clinical Milestones — Feb 19, 2026

Recent PHIO Insider Trades

Bitterman Robert J bought 5.00K (~$5.15K) on Dec 31, 2025.
Bitterman Robert J bought 5.00K (~$5.10K) on Dec 23, 2025.
Bitterman Robert J bought 5.00K (~$5.70K) on Nov 21, 2025.

PHIO Analyst Consensus

1 analysts cover PHIO: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.00.

Common questions about PHIO

Who owns PHIO stock?: Hedge funds tracked by Rallies that own PHIO include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Phio Pharmaceuticals Corp. Common Stock.
Does Rallies show 13F holders for PHIO?: Yes. Rallies tracks hedge fund and 13F ownership data for PHIO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PHIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PHIO. It does not provide personalized investment advice.